Skip to search formSkip to main contentSkip to account menu

pralnacasan

Known as: (1S,9S)-N-((2R,3S)-2-Ethoxy-5-oxotetrahydrofuran-3-yl)-9-((isoquinolin-1-ylcarbonyl)amino)-6,10-dioxooctahydro-6-H-pyridazino(1,2-a)(1,2)diazepine-1-carboxamide, N-((2R,3S)-2-ethoxytetrahydro-5-oxo-3-furanyl)octahydro-9-((1-isoquinolinylcarbonyl)maino)-6,10-dioxo-(1S,9S)-6H-pyridazino(1,2-a)(1,2)diazepine-1-carboxamide 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

AzepinesIsoquinolinesPyridazines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Die Rolle des NLRP3-Inflammasoms in der Pathogenese entzündlicher Erkrankungen am Beispiel von Atherosklerose und der experimentellen Colitis
Background The proinflammatory cytokines interleukin 1b (IL-1b) and IL-18 are central players in the pathogenesis of inflammatory… 
2006
2006
Retard formulation for pralnacasan
The present invention is at least one layer drug 1S, 9S, (RS, 3S) (2-ethoxy-5-oxo-tetrahydro-furan-3-yl) -6,10- dioxo-9-N… 
2006
2006
Delayed release formulation for pralnacasan.
A delayed release tablet consisting of at least two layers, wherein at least one layer delivers the drug (1S, 9S) - (RS, 3S) -N… 
2006
2006
Der Interleukin-1β-converting-enzyme-Inhibitor Pralnacasan reduziert die Dextran-Sulfat-Sodium-induzierte Kolitis und die IL-18-vermittelte Th1-Zell-Aktivierung
The proinflammatory cytokines interleukin (IL)-1beta and IL-18 are supposed to play a crucial role in the pathogenesis of human… 
2006
2006
An extended release formulation for pralnacasan
2005
2005
Sustained-release formulation for pralnacasan
Release tablet, consisting of at least two layers, characterized in that at least one layer, the drug 1S, 9S (RS, 3S) N- (2… 
2005
2005
Synergistische therapeutische Wirkung durch Inhibition der Phosphodiesterase VI und des Interleukin-1β converting Enzyms im murinen Kolitismodell
Abstract This study examined new strategies for pharmacological treatment in a mouse model of chronic inflammatory bowel disease… 
2003
2003
Gateways to clinical trials.
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… 
2003
2003
Pralnacasan improves experimental murine colitis JPET # 57059 1 The ICE inhibitor pralnacasan reduces dextran sulfate sodium-induced murine colitis and Th 1 T-cell activation
2002
2002
Pralnacasan: anti-inflammatory effects in RA
  • 2002
  • Corpus ID: 195131434